Beneficial Ownership Report · SCHEDULE 13G/A
Cardiol Therapeutics Inc.
Beneficial Ownership Report
Structured filing — SCHEDULE 13G/A
primary_doc.xml
Amendment · This filing reports the amendment as submitted.
Subject company
- Company
- Cardiol Therapeutics Inc.
- Company CIK
- 0001702123
- Street
- 602-2265 UPPER MIDDLE ROAD EAST
- Street (continued)
- 602-2265 UPPER MIDDLE ROAD EAST
- City
- OAKVILLE
- State / country code
- A6
- Postal code
- L6H 0G5
Statement details
- Amendment number
- 1
- Security class
- Class A Common Shares
- Event date
- 09/02/2026
- Rule designation
- Rule 13d-1(b)
Reporting person 1
- Name
- Tejara Capital Ltd
- Citizenship / organization
- X0
- Reporting person type
- OO
- Aggregate amount owned
- 6,382,551.00
- Percent of class
- 5.3
- Sole voting power
- 0.00
- Shared voting power
- 0.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 6,382,551.00
- Comments
- Fund Manager authorised by FCA in UK
Item 1
Issuer
Cardiol Therapeutics Inc.
Principal executive office address
602-2265 UPPER MIDDLE ROAD EAST, 602-2265 UPPER MIDDLE ROAD EAST, OAKVILLE, ONTARIO, CANADA, L6H 0G5.
Item 2
Citizenship
i. Cayman ii. United Kingdom
Filing person
i. Trefoil Select Funds SPC-Stylus SP ii. Tejara Capital Limited
Principal business or residence address
i. C/O Apex Funds Services Cayman Ltd, 3rd Floor, Citrus Gove Building, 106 Goring Ave, Grand Cayman, George Town KY1-1001, Cayman Islands ii. 4th Floor, 40 Grosvenor Gardens, London SW1W 0EB, United Kingdom
Item 3
Not applicable indication
N
Type of filing person
FI
Item 4
Percent of class
5.3
Amount beneficially owned
6,382,551
Sole voting power
0
Shared voting power
0
Sole dispositive power
0
Shared dispositive power
6,382,551
Item 5
Not applicable indication
Y
Item 6
Not applicable indication
Y
Item 7
Not applicable indication
Y
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to a fund manager authorised and regulated by the FCA in the UK is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution(s). I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.
Signature 1
- Reporting person
- Tejara Capital Ltd
- Signed
- Miyan Mansur Mannan
- Title
- DIRECTOR
- Date
- 09/23/2026
Company context
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company's lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular innate immune system response known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.